Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
- Peter Lynch
What is insider trading>>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
Passage Bio, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
702712100
(CUSIP Number)
December 31, 2021
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
| ☐ | Rule 13d-1(b) |
| ☐ | Rule 13d-1(c) |
| ☒ | Rule 13d-1(d) |
| * | The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. |
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|
CUSIP No. 702712100 |
13G/A |
Page 2 of 9 Pages |
| 1 |
NAMES OF REPORTING PERSONS/I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) LAV Prescience Limited (“LAVPRE”)
| |
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a) ☐ (b) ☒
|
| 3 |
SEC USE ONLY
| |
| 4 |
CITIZENSHIP OR PLACE OF ORGANIZATION British Virgin Islands
| |
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5 |
SOLE VOTING POWER 2,199,676 shares, except that Yi Shi, the managing partner of LAVPRE, may be deemed to have shared power to vote these shares.
|
| 6 |
SHARED VOTING POWER See response to row 5.
| |
| 7 |
SOLE DISPOSITIVE POWER 2,199,676 shares, except that Yi Shi, the managing partner of LAVPRE, may be deemed to have shared power to dispose of these shares.
| |
| 8 |
SHARED DISPOSITIVE POWER See response to row 7.
|
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,199,676
| |
| 10 |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
|
☐ |
| 11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.1% (1)
| |
| 12 |
TYPE OF REPORTING PERSON OO
| |
| (1) | This percentage is calculated based upon 54,106,911 shares of common stock outstanding of Passage Bio, Inc. (the “Issuer”), as set forth in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on November 4, 2021. |
|
CUSIP No. 702712100 |
13G/A |
Page 3 of 9 Pages |
| 1 |
NAMES OF REPORTING PERSONS/I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) LAV Biosciences Fund V sub A, L.P. (“FUNDVSUBA”)
| |
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) ☐ (b) ☒
|
| 3 |
SEC USE ONLY
| |
| 4 |
CITIZENSHIP OR PLACE OF ORGANIZATION United States
| |
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5 |
SOLE VOTING POWER 0
|
| 6 |
SHARED VOTING POWER 0
| |
| 7 |
SOLE DISPOSITIVE POWER 0
| |
| 8 |
SHARED DISPOSITIVE POWER 0
|
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0
| |
| 10 |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |
☐
|
| 11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0%
| |
| 12 |
TYPE OF REPORTING PERSON PN
| |
|
CUSIP No. 702712100 |
13G/A |
Page 4 of 9 Pages |
| 1 |
NAMES OF REPORTING PERSONS/I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Yi Shi
| |
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) ☐ (b) ☒
|
| 3 |
SEC USE ONLY
| |
| 4 |
CITIZENSHIP OR PLACE OF ORGANIZATION United States
| |
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH |
5 |
SOLE VOTING POWER 0 shares.
|
| 6 |
SHARED VOTING POWER 2,199,676 shares directly owned by LAVPRE. Yi Shi, the managing partner of LAVPRE, may be deemed to have shared power to vote these shares.
| |
| 7 |
SOLE DISPOSITIVE POWER 0 shares.
| |
| 8 |
SHARED DISPOSITIVE POWER 2,199,676 shares directly owned by LAVPRE. Yi Shi, the managing partner of LAVPRE, may be deemed to have shared power to dispose of these shares.
|
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,199,676
| |
| 10 |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |
☐
|
| 11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.1% (1)
| |
| 12 |
TYPE OF REPORTING PERSON IN
| |
| (1) | This percentage is calculated based upon 54,106,911 shares of common stock outstanding of Passage Bio, Inc. (the “Issuer”), as set forth in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on November 4, 2021. |
|
CUSIP No. 702712100 |
13G/A |
Page 5 of 9 Pages |
| Item 1(a) | Name of Issuer: |
Passage Bio, Inc. (the “Issuer”)
| Item 1(b) | Address of Issuer’s Principal Executive Offices: |
Two Commerce Square, 2001 Market Street, 28th Floor
Philadelphia, PA 19103
| Item 2(a) | Name of Persons Filing: |
This Statement is filed by LAV Prescience Limited (“LAVPRE”), LAV Biosciences Fund V sub A, L.P. (“FUNDVSUBA”), and Dr. Yi Shi. The foregoing entities and individual are collectively referred to as the “Reporting Persons.”
Dr. Shi is the managing partner of LAVPRE and FUNDVSUBA, and may be deemed to have shared power to vote and shared power to dispose of shares of the Issuer directly owned by LAVPRE and FUNDVSUBA.
| Item 2(b) | Address of Principal Business Office or, If None, Residence: |
The address for LAVPRE and Dr. Shi is Room 606-7, St. George’s Building, 2 Ice House Street, Central, Hong Kong.
The address of FUNDVSUBA is 2735 Sand Hill Road, Suite 210, Menlo Park, CA 94025.
| Item 2(c) | Citizenship: |
LAVPRE is a British Virgin Islands business company. FUNDVSUBA is a United States partnership. Dr. Shi is a United States citizen.
| Item 2(d) | Title of Class of Securities: |
Common Stock, $0.0001 par value per share
| Item 2(e) | CUSIP Number: |
CUSIP #702712100
| Item 3. | Not applicable. |
| Item 4. | Ownership |
The following information with respect to the ownership of the Common Stock of the Issuer by the Reporting Persons is provided as of December 31, 2021:
| (a) | Amount beneficially owned: |
See Row 9 of cover page for each Reporting Person.
| (b) | Percent of Class: |
See Row 11 of cover page for each Reporting Person.
| (c) | Number of shares as to which such person has: |
| (i) | Sole power to vote or to direct the vote: |
See Row 5 of cover page for each Reporting Person.
|
CUSIP No. 702712100 |
13G/A |
Page 6 of 9 Pages |
| (ii) | Shared power to vote or to direct the vote: |
See Row 6 of cover page for each Reporting Person.
| (iii) | Sole power to dispose or to direct the disposition of: |
See Row 7 of cover page for each Reporting Person.
| (iv) | Shared power to dispose or to direct the disposition of: |
See Row 8 of cover page for each Reporting Person.
| Item 5. | Ownership of Five Percent or Less of a Class |
Not applicable.
| Item 6. | Ownership of More Than Five Percent on Behalf of Another Person |
Not applicable.
| Item 7. | Identification and Classification of Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person |
Not applicable.
| Item 8. | Identification and Classification of Members of the Group |
Not applicable.
| Item 9. | Notice of Dissolution of Group |
Not applicable.
| Item 10. | Certifications |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
|
CUSIP No. 702712100 |
13G/A |
Page 7 of 9 Pages |
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: February 9, 2022
| LAV Prescience Limited | ||
| By: | /s/ Yi Shi | |
| Name: | Yi Shi | |
| Title: | Managing Partner | |
| LAV Biosciences Fund V sub A, L.P. | ||
| By: | /s/ Yi Shi | |
| Name: | Yi Shi | |
| Title: | Managing Partner | |
| Yi Shi | |
| /s/ Yi Shi | |
Yi Shi |
|
CUSIP No. 702712100 |
13G/A |
Page 8 of 9 Pages |
EXHIBIT INDEX
| Exhibit | Found on Sequentially | Numbered Page | ||
| Exhibit A: | Agreement of Joint Filing | 9 |
|
CUSIP No. 702712100 |
13G |
Page 9 of 9 Pages |
Agreement of Joint Filing
The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock of Passage Bio, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G.
Dated: February 9, 2022
| LAV Prescience Limited | ||
| By: | /s/ Yi Shi | |
| Name: | Yi Shi | |
| Title: | Managing Partner | |
| LAV Biosciences Fund V sub A, L.P. | ||
| By: | /s/ Yi Shi | |
| Name: | Yi Shi | |
| Title: | Managing Partner | |
| Yi Shi | |
| /s/ Yi Shi | |
Yi Shi |